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HEALTH ECONOMIC EVALUATION OF PATIENTS WITH
RHEUMATOID ARTHRITIS (RA) TREATED WITH ADALIMUMAB
Vanoverbeke N1, Annemans L1, Cauchie P2, Hendrickx E2
1HEDM, Meise, Belgium; 2Abbott, Ottignies, Belgium
OBJECTIVES: To assess the cost-effectiveness of adalimumab
versus etanercept in the management of Belgian patients with
moderate to severe RA. Adalimumab is a human anti-TNF mon-
oclonal antibody and is administered every other week, in com-
bination with methotrexate (MTX) or other disease-modifying
antirheumatic drugs, or as monotherapy. Two scenarios were
developed: one for which each TNF-antagonist was combined
with MTX, and one for which each was given as monotherapy.
METHODS: An incidence-based Markov model was created in
MS-Excel, reﬂecting the current treatment strategies and their
associated outcomes. ACR response rates were obtained for
adalimumab and etanercept from pivotal clinical trials. After
adjustment for differences in trial populations according to 
the Choi-method, 42.1% of adalimumab-monotherapy patients,
66.7% of adalimumab plus MTX patients, 60.1% of etanercept-
monotherapy patients, and 65.6% of etanercept plus MTX
patients achieved a ≥20% improvement in ACR criteria. Second-
line inﬂiximab therpy and a return to watchful-waiting in case
of inadequate response and/or adverse events were also consid-
ered. Estimated resource use was provided by 6 rheumatologists.
Effectiveness was expressed in QALYs, and calculated according
to a validated method (Boggs) from HAQ-DI scores for ACR20
responders and non-responders. The analysis spanned 3 years.
RESULTS: Etanercept plus MTX and adalimumab plus MTX
generated comparable utilities (1.284 vs. 1.287 QALYs), at a
slightly higher cost for etanercept (38,970€ vs. 38,578€). An
analysis of both as monotherapies resulted in a cost of 28,757€
and 1.138 QALYs for etanercept, and 22,784€ and 1.052 QALYs
for adalimumab. The associated incremental cost-effectiveness
was 69,971€, based on price-parity. Sensitivity analyses showed
that results were sensitive toward variations in AE rates,
response rates of second-line inﬂiximab, and modiﬁcations in the
administration modalities of adalimumab. However, these sensi-
tivities did not affect the comparative results. CONCLUSIONS:
Adalimumab is comparably effective and cost-effective to etan-
ercept, but at a slightly to moderately lower cost.
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A COST MINIMISATION ANALYSE FOR STUDYING THE
EFFICIENCY OF BIOLOGIC THERAPIES (BT) IN RHEUMATOID
ARTHRITIS (RA). OVERVIEW FOR THE SPANISH SETTING
Badia X1, Serrano D1, Magaz S2
1Health Outcomes Research Europe, Barcelona, Barcelona, Spain;
2Health Outcomes Policy and Economics, Barcelona, Spain
OBJECTIVE: Adalimumab is a new fully human anti-TNFá
monoclonal antibody used to treat moderate to severe rheuma-
toid arthritis (RA). Adalimumab, just like the other biological
therapies (BT), for RA, etanercept and inﬂiximab, has proved to
be effective and safe in randomised clinical trials. These BT have
different administration routes and dosage proﬁles so their use
might have a different economic impact for health care budgets.
There is no evidence about the relative efﬁciency of the available
BT in the Spanish setting and the objective of this research was
to undertake an economic evaluation of the three therapies.
METHODS: Under the assumption of similar efﬁcacy rates, a
cost minimisation analysis was performed under the perspective
of the Spanish NHS and a time horizon of 1 year, thus only
including direct health care costs for the administration of the
drugs and the management of adverse events. The adverse events
incidences were classiﬁed as mild, moderate and severe, and were
taken into account as a random variables in order to collect the
uncertainly. A decision-analysis model was developed to simu-
late a cohort of 5000 patients in each iteration so statistically
signiﬁcant differences could be assessed. Data on the incidence
of adverse events with each drug was retrieved from randomised
clinical trials. Data on resource use was extracted from an expert
panel of 2 specialists and data on unit costs from published
sources. RESULTS: The mean costs per patient treated were
17,229€ for inﬂiximab, 14,289€ for etanercept, and 13,845€ for
adalimumab. Differences were statistically signiﬁcant (p = 0.00)
in all 10 simulations that were conducted. CONCLUSION: In
our analyses Adalimumab was the most efﬁcient biologic therapy
in patients with AR, that have failed therapy with at least one
disease-modifying antirheumatic drugs (DMARD’s).
PAR10
PATTERNS OF DOSING WITH ADALIMUMAB AMONG
COMMERCIALLY INSURED PATIENTS
Ollendorf DA, Lidsky L, Zhao J
PharMetrics, Inc, Watertown, MA, USA
OBJECTIVES: To conduct a descriptive examination of patterns
of dosing with adalimumab among a cohort of commercially-
insured patients to assess whether dosing frequency in clinical
practice is consistent with standard labeling. METHODS: Data
were obtained from the PharMetrics Patient-Centric Database,
which contains integrated medical and pharmacy claims data for
approximately 43 million unique patients from 74 health plans
across the U.S. All patients with two or more prescriptions for
adalimumab during the period January–December 2003 were
initially identiﬁed and followed for up to 11 months. Dosing fre-
quency was expressed based on the average number of calendar
days between injections, which was calculated by dividing the
number of elapsed days between prescription claims by the quan-
tity supplied (i.e., number of syringes) for the prescription initi-
ating the interval. Injection frequency was tracked over time
based on patients available at each prescription interval, and was
also measured speciﬁcally among patients with at least six pre-
scription intervals (i.e., seven consecutive prescriptions). For 
this calculation, the percentage of patients with time between
injections that approximated every-week (0–11 days) vs. every-
other-week (12 days or more) dosing was calculated. RESULTS:
A total of 527 patients were available for analysis. The mean 
age of the sample was 51.3 years; 76.1% were female. The
average number of days between injections declined substantially
over time, from 16.2 days at the ﬁrst interval (N = 527) to 12.5
days at the 10th interval (N = 27). As of the sixth interval, 34
patients (23.8%) were receiving injections on an approximate
every-week basis, while the remaining 109 patients (76.2%) were
dosed every other week. CONCLUSIONS: The results of this
analysis suggest that the time between adalimumab injections
may decline over multiple treatments; furthermore, after sub-
stantial use of adalimumab, up to one-quarter of patients may
require injections more frequently than what is stipulated in the
labeling.
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A COST EFFICACY ANALYSIS ON ANTI-TNF THERAPY IN
ANKYLOSING SPONDYLITIS
Singh G1,Tandon N2, Bala M2
1Stanford University Medical School, Palo Alto, CA, USA; 2Centocor,
Inc, Horsham, PA, USA
OBJECTIVE: To estimate the cost-efﬁcacy of inﬂiximab and
etanercept compared to placebo in patients with ankylosing
